Daily cardiology

DiaBeat: The Beating Heart of Diabetes (7th session), a scientific debate 14.01.2022 1:56:44 ↓

7th Diabetes Masterclass for Cardiologists

Antithrombotic lighthouse, Cases and Faces: antithrombotic therapy in CAD 14.01.2022 1:45:57 ↓

Antithrombotic regimens in CAD

From optimal medical therapy to revascularization in CCS 14.01.2022 49:01 ↓

Choosing the best therapeutic strategy in CCS

Cardiovascular complications of T2DM: the preventive role of SGLT2Is 14.01.2022 29:16 ↓

SGLT2Is and the prevention of cardiovascular complications in T2DM

Cardiometabolic Grand Round (4) 14.01.2022 54:39 ↓

Guideline-directed cardiovascular evaluations before surgery

DCS 1400: session 8, Valvular Heart disease 14.01.2022 1:40:01 ↓

The eighth panel of DCS 1400: Valvular Heart disease

Tailored Antithrombotic therapy for CCS patients 14.01.2022 25:25 ↓

Best individual antithrombotic strategy in CCS

The evolution of antiplatelet therapy in CAD: a 45 year journey 14.01.2022 15:22 ↓

A brief history of anti-platelet therapy in CAD

Dual antiplatelet therapy in2021: Current recommendations 14.01.2022 1:33:53 ↓

The latest updates on DAPT

How to reduce the atherosclerotic cardiovascular risk 14.01.2022 1:30:22 ↓

A case-based Review on HTN and DLP management

DiaBeat: The Beating Heart of Diabetes (1st session) 14.01.2022 2:01:02 ↓

1st Diabetes Masterclass for Cardiologists

PCSK9 inhibitors place in patients with cardiometabolic diseases 14.01.2022 46:51 ↓

PCSK9 inhibitors from two perspectives of Endocrinologist & Cardiologist

Residents’ Island: Abidi CVD Prevention Academy 14.01.2022 2:06:19 ↓

Multidisciplinary approach to CVD Prevention

Cardiometabolic Grand Round (3) 13.01.2022 58:29 ↓

A brief talk on DM medication challenges in patients with CVD

7th Case: Thrombocytopenia 13.01.2022 5:52 ↓

Any Concerns for OACs Use in Patients with Thrombocytopenia

5th Case: Stable ASCVD 13.01.2022 9:00 ↓

Low dose Rivaroxaban in SIHD, COMPASS trial

6th Case: Hepatic Impairment 13.01.2022 5:38 ↓

OAC of choice in patients with hepatic impairment, any difference between DOACs?

8th Case: Intracranial Bleed 13.01.2022 7:39 ↓

OAC Choice in High Thrombotic Risk Patients after ICH

10th Case: Drug Drug Interactions 13.01.2022 6:38 ↓

DOACs important interactions in clinical practice

9th Case: Renal Insufficiency 13.01.2022 9:21 ↓

OAC Management in Patients with CKD

4th Case: Extreme Body Weights 13.01.2022 9:33 ↓

OAC choice in patients with obesity or low body weights, any role for DOACs?

3rd Case: AF & Artificial Heart Valves 13.01.2022 11:30 ↓

OAC of choice in patients with artificial heart valves

2nd Case: Cancer associated VTE 13.01.2022 12:58 ↓

Anticoagulation of choice in patients with cancer, the importance of DDI

1st Case: Elective PCI and AF 13.01.2022 12:57 ↓

Antithrombotic regimen of choice in patients with AF undergoing elective PCI

SGLT2 inhibition: A snapshot into their evolution 13.01.2022 26:51 ↓

Endocrinologist Perspective on SGLT2 inhibitors